Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2006 1
2007 1
2008 3
2009 9
2010 78
2011 1008
2012 2155
2013 2468
2014 2597
2015 2630
2016 2847
2017 3179
2018 3410
2019 1886
2020 59
Text availability
Article attribute
Article type
Publication date

Search Results

18,734 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab (Keytruda)
Kwok G, et al. Hum Vaccin Immunother 2016 - Review. PMID 27398650 Free PMC article.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
D'Angelo SP, et al. Lancet Oncol 2018 - Clinical Trial. PMID 29370992 Free PMC article.
Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. ...
Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety o …
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Baker KF and Isaacs JD. Ann Rheum Dis 2018 - Review. PMID 28765121
Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their application to the treatment of IMIDs....
Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their a …
Adalimumab for the treatment of uveitis
LaMattina KC and Goldstein DA. Expert Rev Clin Immunol 2017 - Review. PMID 28140700
18,734 results
Jump to page
Feedback